Begley CE, Durgin TL. The direct cost of epilepsy in the United States: A systematic review of estimates. Epilepsia. 2015;56(9):1376–87. https://doi.org/10.1111/epi.13084.

Article  PubMed  Google Scholar 

Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med. 2000;342(5):314–9. https://doi.org/10.1056/nejm200002033420503.

Article  CAS  PubMed  Google Scholar 

Perucca E, Alexandre V, Jr., Tomson T. Old versus new antiepileptic drugs: the SANAD study. Lancet (London, England). 2007;370(9584):313; author reply 5–6. https://doi.org/10.1016/s0140-6736(07)61149-0.

Epilepsy CAA. Clinical diagnosis and treatment guidelines: Epilepsy fascicle. Beijing: People’s Health Publishing House; 2015.

Google Scholar 

Ng YT, Collins SD. Clobazam. Neurotherapeutics. 2007;4(1):138–44. https://doi.org/10.1016/j.nurt.2006.11.002.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Allen JW, Oxley J, Robertson MM, et al. Clobazam as adjunctive treatment in refractory epilepsy. Br Med J (Clin Res Ed). 1983;286(6373):1246–7. https://doi.org/10.1136/bmj.286.6373.1246.

Article  CAS  PubMed  Google Scholar 

Keene DL, Whiting S, Humphreys P. Clobazam as an add-on drug in the treatment of refractory epilepsy of childhood. Can J Neurol Sci Le J Canadien des sciences neurologiques. 1990;17(3):317–9. https://doi.org/10.1017/s0317167100030651.

Article  CAS  Google Scholar 

Koeppen D, Baruzzi A, Capozza M, et al. Clobazam in therapy-resistant patients with partial epilepsy: a double-blind placebo-controlled crossover study. Epilepsia. 1987;28(5):495–506. https://doi.org/10.1111/j.1528-1157.1987.tb03678.x.

Article  CAS  PubMed  Google Scholar 

Schmidt D, Rohde M, Wolf P, et al. Clobazam for refractory focal epilepsy. A controlled trial. Arch Neurol. 1986;43(8):824–6. https://doi.org/10.1001/archneur.1986.00520080064023.

Article  CAS  PubMed  Google Scholar 

Conry JA, Ng YT, Paolicchi JM, et al. Clobazam in the treatment of Lennox-Gastaut syndrome. Epilepsia. 2009;50(5):1158–66. https://doi.org/10.1111/j.1528-1167.2008.01935.x.

Article  CAS  PubMed  Google Scholar 

Ng YT, Conry JA, Drummond R, et al. Randomized, phase III study results of clobazam in Lennox-Gastaut syndrome. Neurology. 2011;77(15):1473–81. https://doi.org/10.1212/WNL.0b013e318232de76.

Article  CAS  PubMed  Google Scholar 

Ng YT, Conry J, Paolicchi J, et al. Long-term safety and efficacy of clobazam for Lennox-Gastaut syndrome: interim results of an open-label extension study. Epilepsy Behav E&B. 2012;25(4):687–94. https://doi.org/10.1016/j.yebeh.2012.09.039.

Article  Google Scholar 

FDA approves Onfi™ (clobazam) for the adjunctive treatment of seizures associated with Lennox-Gastaut Syndrome. https://www.europeanpharmaceuticalreview.com/news/9653/fda-approves-onfi-clobazam-for-the-adjunctive-treatment-of-seizures-associated-with-lennox-gastaut-syndrome/. Accessed 01 May 2023.

Cross JH, Auvin S, Falip M, et al. Expert opinion on the management of Lennox-Gastaut syndrome: treatment algorithms and practical considerations. Front Neurol. 2017;8:505. https://doi.org/10.3389/fneur.2017.00505.

Article  PubMed  PubMed Central  Google Scholar 

Montouris G, Aboumatar S, Burdette D, et al. Expert opinion: proposed diagnostic and treatment algorithms for Lennox-Gastaut syndrome in adult patients. Epilepsy Behav E&B. 2020;110: 107146. https://doi.org/10.1016/j.yebeh.2020.107146.

Article  Google Scholar 

Jamil A, Levinson N, Gelfand M, et al. Efficacy and tolerability of Clobazam in adults with drug-refractory epilepsy. Neurol Clin Pract. 2021;11(5):e669–76. https://doi.org/10.1212/cpj.0000000000000992.

Article  PubMed  PubMed Central  Google Scholar 

Clements KM, Skornicki M, O’Sullivan AK. Cost-effectiveness analysis of antiepileptic drugs in the treatment of Lennox-Gastaut syndrome. Epilepsy Behav E&B. 2013;29(1):184–9. https://doi.org/10.1016/j.yebeh.2013.07.011.

Article  Google Scholar 

Skornicki M, Clements KM, O’Sullivan AK. Budget impact analysis of antiepileptic drugs for Lennox-Gastaut syndrome. J Managed Care Special Pharmacy. 2014;20(4):400–6.

Article  Google Scholar 

Kwan P, Arzimanoglou A, Berg AT, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc task force of the ILAE commission on therapeutic strategies. Epilepsia. 2010;51(6):1069–77. https://doi.org/10.1111/j.1528-1167.2009.02397.x.

Article  CAS  PubMed  Google Scholar 

National Bureau of Statistics of the People's Republic of China. . http://www.stats.gov.cn/. Accessed 07 Aug 2023.

Guoen L. China guidelines for pharmacoeconomic evaluations. Beijing: China Market Press; 2020.

Google Scholar 

Aalabaf-Sabaghi M. Decision modelling for health economic evaluation. J Epidemiol Community Health. 2007. https://doi.org/10.1136/jech.2007.059576.

Article  PubMed Central  Google Scholar 

Neligan A, Bell GS, Elsayed M, et al. Treatment changes in a cohort of people with apparently drug-resistant epilepsy: an extended follow-up. J Neurol Neurosurg Psychiatry. 2012;83(8):810–3. https://doi.org/10.1136/jnnp-2011-302085.

Article  PubMed  Google Scholar 

National Bureau of Statistics of the People's Republic of China. Seventh population census data. 2021. https://www.stats.gov.cn/sj/pcsj/rkpc/7rp/zk/indexch.htm. Accessed 27 Sep 2024.

Trinka E, Bauer G, Oberaigner W, et al. Cause-specific mortality among patients with epilepsy: results from a 30-year cohort study. Epilepsia. 2013;54(3):495–501. https://doi.org/10.1111/epi.12014.

Article  PubMed  Google Scholar 

Flint I, Medjedovic J, Drogon O’Flaherty E, et al. Mapping analysis to predict SF-6D utilities from health outcomes in people with focal epilepsy. Eur J Health Econ. 2023;24(7):1061–72. https://doi.org/10.1007/s10198-022-01519-w.

Article  PubMed  Google Scholar 

Laskier V, Agyei-Kyeremateng KK, Eddy AE, et al. Cost-effectiveness of cenobamate for focal seizures in people with drug-resistant epilepsy. Epilepsia. 2023;64(4):843–56. https://doi.org/10.1111/epi.17506.

Article  PubMed  Google Scholar 

Sang T, Xiang T, Zhu SN, et al. Treatment-related costs of childhood epilepsy in mainland China: a preliminary study in a tertiary pediatric epilepsy center. J Child Neurol. 2019;34(2):68–73. https://doi.org/10.1177/0883073818811176.

Article  PubMed  Google Scholar 

Multi-disciplinary Team for Rare Diseases, Peking Union Medical College Hospital National Rare Diseases Committee. Expert Consensus on Clobazam in theTreatment of Refractory Epilepsy(2022). 2022;13(05):768–82.

Yao J, Guan X, Zang Y, et al. Treatment and practice of correlation parameters in probabilistic sensitivity analysis of pharmacoeconomics. Drug Eval China. 2019;36(02):150–5. https://doi.org/10.3969/j.issn.2095-3593.2019.02.025.

Article  Google Scholar 

State Drug Administration of the People's Republic of China. . https://www.nmpa.gov.cn/. Accessed 08 Aug 2023.

Toledo M, Beale R, Evans JS, et al. Long-term retention rates for antiepileptic drugs: A review of long-term extension studies and comparison with brivaracetam. Epilepsy Res. 2017;138:53–61. https://doi.org/10.1016/j.eplepsyres.2017.10.008.

Article  CAS  PubMed  Google Scholar 

Elliott J, McCoy B, Clifford T, et al. Economic evaluation of stiripentol for dravet syndrome: a cost-utility analysis. Pharmacoeconomics. 2018;36(10):1253–61. https://doi.org/10.1007/s40273-018-0669-7.

Article  PubMed  Google Scholar 

Miot J, Thiede M. Adapting pharmacoeconomics to shape efficient health systems en route to UHC - lessons from two continents. Front Pharmacol. 2017;8:715. https://doi.org/10.3389/fphar.2017.00715.

Article  PubMed  PubMed Central  Google Scholar 

Borghs S, Beaty S, Parekh W, et al. Cost of epilepsy-related health care encounters in the United States. J Manag Care Special Pharmacy. 2020;26(12):1576–81.

Article  Google Scholar 

Specialized Committee on Innovation and Translation. Chinese association against epilepsy. Chinese Exp Cons Diagn Treat Lennox-Gastaut Synd. 2022;8(03):187–95.

Google Scholar 

Administration NMP. Notice of the State Administration for Food and Drug Administration, Ministry of Public Security, and National Health and Family Planning Commission on Publishing the Catalogue of Anesthetic and Psychotropic Drugs. 2013. https://www.nmpa.gov.cn/xxgk/fgwj/gzwj/gzwjyp/20131111120001419.html. Accessed 07 Dec 2023.

Administration NMP. Notice on Issuing the Temporary Import Work Plan for Clinical Urgent Drugs and the Temporary Import Work Plan for Chlorphenicol. 2022. https://www.nmpa.gov.cn/xxgk/fgwj/qita/20220628165440148.html. Accessed 07 Jul 2023.